Drug Profile
Sepantronium bromide
Alternative Names: YM-155; YM155 monobromideLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antineoplastics; Naphthoquinones; Small molecules
- Mechanism of Action BIRC5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Diffuse large B cell lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 13 May 2022 Pharmacodynamics data from a preclinical trial in Renal cell carcinoma presented at the 117th Annual Meeting of the American Urological Association
- 11 Dec 2021 Pharmacodynamics data from a preclinical trial in Cancer presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
- 03 Dec 2016 Pharmacodynamics data from a preclinical studies in Non-Hodgkin's lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology